- Stocks
- Pharma & Healthcare
- Kimia Bio
Kimia Bio share price
NSE: KIMIABLPharma & HealthcareDrug Manufacturers - Specialty & Generic
Kimia Bio at a glance
With a market capitalisation of ₹152 Cr, it ranks 2434th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 96.5% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹27 Cr (−28.9% year on year) and net profit ₹0 Cr (−81.4%), on a standalone basis. Promoters held 74.94% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹152 CrRank 2434 on NSE
- Price to book
- 20.18×FY25
- EPS (TTM)
- ₹1.64to Q4 FY26
- ROE
- 96.5%FY25
- ROCE
- 61.9%FY25
- Debt to equity
- 3.27FY25
- Net profit margin
- 8.1%FY25
- Book value / share
- ₹2.11FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Kimia Bio quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹22 Cr | ₹28 Cr | ₹30 Cr | ₹38 Cr | ₹24 Cr | ₹34 Cr | ₹30 Cr | ₹27 Cr |
| Revenue YoY | −7.6% | +16.4% | +15.1% | +26.2% | +5.3% | +20.7% | 0.0% | −28.9% |
| Net profit | ₹1 Cr | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹0 Cr |
| Net profit YoY | — | — | — | +10.6% | −58.3% | −36.6% | +19.0% | −81.4% |
| Net margin | 6.4% | 5.7% | 15.2% | 5.2% | 2.5% | 3.0% | 18.1% | 1.4% |
| EPS | ₹0.30 | ₹0.34 | ₹0.97 | ₹0.42 | ₹0.13 | ₹0.21 | ₹1.15 | ₹0.15 |
Kimia Bio financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹106 Cr | ₹133 Cr | ₹125 Cr | ₹129 Cr | ₹105 Cr | ₹119 Cr |
| Operating profit | ₹1 Cr | ₹6 Cr | −₹5 Cr | −₹11 Cr | −₹7 Cr | ₹14 Cr |
| Net profit | ₹1 Cr | ₹5 Cr | −₹4 Cr | −₹9 Cr | −₹5 Cr | ₹10 Cr |
| EPS (₹) | ₹0.32 | ₹1.08 | −₹0.78 | −₹1.98 | −₹1.12 | ₹2.03 |
| Cash from operations | ₹0 Cr | ₹6 Cr | ₹0 Cr | −₹7 Cr | ₹15 Cr | ₹21 Cr |
| Total debt | ₹24 Cr | ₹28 Cr | ₹24 Cr | ₹31 Cr | ₹21 Cr | ₹10 Cr |
| Shareholders' equity | ₹13 Cr | ₹18 Cr | ₹15 Cr | ₹11 Cr | ₹6 Cr | ₹16 Cr |
Kimia Bio shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| Domestic institutions | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
| Non-institutions | 24.68% | 24.68% | 24.68% | 24.68% | 24.68% | 24.68% |
Kimia Bio vs peers
The listed Pharma & Healthcare companies nearest to Kimia Bio by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| NATCAPSUQNatural Capsules | ₹162.00 | +1.25% | −32.2% | ₹169 Cr | — | — |
| PANCHSHEELPanchsheel Org | — | — | — | ₹159 Cr | — | — |
| AUROLABAuro Labs | — | — | — | ₹156 Cr | — | — |
| KIMIABLKimia Bio | — | — | — | ₹152 Cr | — | — |
| SMRUTHIORGSmruthi Organic | — | — | — | ₹135 Cr | — | — |
Ask anything about Kimia Bio
Pivot answers on the live chart with evidence you can check, and tests strategies against KIMIABL's own history. Try: “Why has KIMIABL moved over the last three months?” · “Backtest a 50-day moving-average crossover on KIMIABL over five years” · “Compare KIMIABL with BALPHARMA on margins and valuation”
Frequently asked questions about Kimia Bio
What is the market cap of Kimia Bio?
Kimia Bio's market capitalisation is ₹152 Cr (₹152 Cr) at the 19 Oct 2026 close, ranking 2434th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Kimia Bio?
Return on equity was 96.5% in FY25 and return on capital employed was 61.9% in FY25 (standalone figures).
Is Kimia Bio a debt-free company?
No. Kimia Bio's debt-to-equity ratio was 3.27 in FY25, with total debt of ₹10 Cr.
What were Kimia Bio's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kimia Bio reported revenue of ₹27 Cr, −28.9% year on year, and net profit of ₹0 Cr, −81.4% year on year.
What is the shareholding pattern of Kimia Bio?
As of 30 Jun 2026: promoters 74.94%, domestic institutions 0.38%, non-institutions 24.68%.
Who are Kimia Bio's competitors?
The listed Pharma & Healthcare companies closest to Kimia Bio by market cap are Bal Pharma, Vaidya Sane Ayu, Natural Capsules, Panchsheel Org, Auro Labs and Smruthi Organic.
Is Kimia Bio a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kimia Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KIMIABL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text